Home
Axcella

Axcella Market Share Analysis for June 2026

Health > Biotechnology and Pharmaceuticals

Domainaxcellatx.com

Year Founded2010

Employees51 - 200

Annual Revenue--

Axcella

Axcella (including company regionals)

axcellatx.com

See more website traffic and engagement information

Total visits to Axcella's top domains

Understand Axcella market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Axcella's top domains

Analyze Axcella engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Axcella's top domains

See how Axcella keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Axcella top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Axcella

These are the website technologies, by industry, used by Axcella top domains

Conversion & Analytics (2)

Google Analytics

Marketing (2)

Google Marketing Platform

Mobile (2)

Meta Viewport

Widget (2)

Yoast SEO

More Technologies

5

See all

News & Signals from Axcella

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAxcella Health, Inc. hired Robert Crane as Chief Financial Officer on Feb 7th '22.Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company’s new Chief Financial Officer.

NewsAxcella Health, Inc. hired Virginia Dean as Senior Vice President and Chief People Officer on Jun 1st '21.Added Virginia Dean as Chief People Officer : In June 2021, Axcella appointed Virginia Dean as the company’s Senior Vice President and Chief People Officer.

NewsAxcella Health, Inc. hired Alison D. Schecter as President of Research and Development on Mar 3rd '21.Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development.